ARYx Therapeutics Inc (ARYX)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

6300 DUMBARTON CIRCLE FREMONT, CA 94555

ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates to eliminate known safety issues associated with commercial drugs. It uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs and are metabolized to avoid specific adverse side effects associated with these compounds. The company has three products in Phase 2 clinical trials: ATI-7505 for the treatment of various gastrointestinal disorders, ATI-5923 for the treatment of patients at risk for the formation of dangerous blood clots, and ATI-2042 for the treatment of atrial fibrillation. It also has multiple product candidates in preclinical development, including ATI-9242 for the treatment of schizophrenia and other psychiatric disorders. The company has collaboration agreement with Procter & Gamble Pharmaceuticals, Inc. for the development and commercialization of ATI-7505.

View SEC Filings from ARYX instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ARYX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ARYX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GROWTH EQUITY OPPORTUNITIES FUND, LLC

NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

NEA 12 GP, LLC

NEWHALL CHARLES W III

KRAMLICH C RICHARD

BARRIS PETER J

PERRY MARK W

BARRETT M JAMES

NEA PARTNERS 12, LIMITED PARTNERSHIP

SANDELL SCOTT D

  • 10% Owner
No longer subject to file 2011-03-10 0

KERINS PATRICK J

  • 10% Owner
No longer subject to file 2011-03-10 0

DRANT RYAN D

  • 10% Owner
No longer subject to file 2011-03-10 0

BASKETT FOREST

  • 10% Owner
No longer subject to file 2011-03-10 0

KOLLURI KRISHNA KITTU

  • 10% Owner
No longer subject to file 2011-03-10 0

EVNIN LUKE

GALAKATOS NICHOLAS

HENNER DENNIS

STEINMETZ MICHAEL

GADICKE ANSBERT

WHEELER KURT

  • 10% Owner
0 2010-09-30 0

SIMON NICHOLAS J III

  • Director
  • 10% Owner
0 2010-09-30 0

MPM BIOVENTURES III-QP L.P.

MPM BIOVENTURES III PARALLEL FUND, L.P.

MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG

MPM BIOVENTURES III L.P.

MPM BIOVENTURES III GP L.P.

MPM BIOVENTURES III LLC

MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC

  • 10% Owner
0 2010-09-30 0

BEIER DAVID W

  • Director
0 2010-04-30 0

SEKHRI PAUL J

  • Director
0 2010-04-30 0

ROSENMAN HERM

  • Director
0 2010-04-30 0

LEONARD KEITH R

  • Director
0 2010-04-30 0

EKMAN LARS

  • Director
0 2010-04-30 0

GODDARD PAUL CHAIRMAN & CEO

  • Officer
  • Director
0 2010-02-25 0

MILNER PETER G PRES., RESEARCH & DEV.

  • Officer
  • Director
0 2010-02-25 0

VARIAN JOHN COO & CFO

  • Officer
0 2010-02-25 0

DRUZGALA PASCAL SR. V.P. & CHIEF SCIEN.OFF.

  • Officer
0 2010-02-25 0

NAGLER DAVID V.P.,CORP. AFFAIRS & SECT.

  • Officer
0 2010-02-25 0

BARKER JASON SR.DIR.& PRINCIPAL ACCTG. OFF.

  • Officer
0 2010-02-17 0

ORBIMED ADVISORS LLC

ISALY SAMUEL D

  • 10% Owner
No longer subject to file 2009-05-22 0

CANAFAX DANIEL V.P. & CDO

  • Officer
0 2009-02-18 0

LINEHAN CHARLES M

  • 10% Owner
4,469,274 2008-11-14 0

TRAINOR III EUGENE A

  • 10% Owner
4,469,274 2008-11-14 0

MPM BIOVENTURES III QP LP

MPM BIOVENTURES III PARALLEL FUND, LP

MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG

MPM BIOVENTURES III LP

MPM BIOVENTURES III GP LP

MPM BIOVENTURES III LLC

MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC

MPM BIOVENTURES STRATEGIC FUND LP

  • 10% Owner
5,364,572 2008-11-14 0

ADELMAN ROBERT J

  • Director
  • 10% Owner
3,340,139 2008-11-14 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments